Free Trial
NASDAQ:LENZ

LENZ Therapeutics Q1 2025 Earnings Report

LENZ Therapeutics logo
$29.52 +0.64 (+2.22%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$29.51 -0.01 (-0.03%)
As of 05/2/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LENZ Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.56
Beat/Miss
N/A
One Year Ago EPS
N/A

LENZ Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

LENZ Therapeutics Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Wednesday, May 7, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

LENZ Therapeutics Earnings Headlines

Elon Set to Shock the World by May 1st ?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believes will be Elon’s greatest invention ever… Yes, even bigger than Tesla or SpaceX.
LENZ Therapeutics (LENZ) Receives a Buy from TD Cowen
Lenz Therapeutics assumed with an Overweight at Piper Sandler
See More LENZ Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like LENZ Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LENZ Therapeutics and other key companies, straight to your email.

About LENZ Therapeutics

LENZ Therapeutics (NASDAQ:LENZ), a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

View LENZ Therapeutics Profile

More Earnings Resources from MarketBeat